X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ACTAVIS (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ACTAVIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
ACTAVIS
Dec-14
GLENMARK PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,26217,549-   
Low Rs67210,705-   
Sales per share (Unadj.) Rs270.63,160.1-  
Earnings per share (Unadj.) Rs24.9-394.4-  
Cash flow per share (Unadj.) Rs34.4289.9-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs151.36,854.2-  
Shares outstanding (eoy) m282.16265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.64.5 79.9%   
Avg P/E ratio x38.9-35.8 -108.5%  
P/CF ratio (eoy) x28.148.7 57.7%  
Price / Book Value ratio x6.42.1 309.9%  
Dividend payout %8.00-   
Avg Mkt Cap Rs m272,7783,756,334 7.3%   
No. of employees `00010.021.6 46.4%   
Total wages/salary Rs m13,7820-   
Avg. sales/employee Rs Th7,614.938,901.8 19.6%   
Avg. wages/employee Rs Th1,374.80-   
Avg. net profit/employee Rs Th700.2-4,854.5 -14.4%   
INCOME DATA
Net Sales Rs m76,340840,278 9.1%  
Other income Rs m356-2,097 -17.0%   
Total revenues Rs m76,696838,181 9.2%   
Gross profit Rs m14,172107,946 13.1%  
Depreciation Rs m2,691181,951 1.5%   
Interest Rs m1,78926,504 6.7%   
Profit before tax Rs m10,048-102,606 -9.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,527 0.0%   
Tax Rs m3,028-5,275 -57.4%   
Profit after tax Rs m7,019-104,858 -6.7%  
Gross profit margin %18.612.8 144.5%  
Effective tax rate %30.15.1 586.3%   
Net profit margin %9.2-12.5 -73.7%  
BALANCE SHEET DATA
Current assets Rs m59,096442,719 13.3%   
Current liabilities Rs m40,018322,872 12.4%   
Net working cap to sales %25.014.3 175.2%  
Current ratio x1.51.4 107.7%  
Inventory Days Days7558 129.2%  
Debtors Days Days11966 179.8%  
Net fixed assets Rs m39,075102,606 38.1%   
Share capital Rs m2820-   
"Free" reserves Rs m30,2810-   
Net worth Rs m42,7031,822,533 2.3%   
Long term debt Rs m24,873955,043 2.6%   
Total assets Rs m111,0263,340,104 3.3%  
Interest coverage x6.6-2.9 -230.4%   
Debt to equity ratio x0.60.5 111.2%  
Sales to assets ratio x0.70.3 273.3%   
Return on assets %7.9-2.3 -338.2%  
Return on equity %16.4-5.8 -285.7%  
Return on capital %17.5-3.0 -581.8%  
Exports to sales %43.30-   
Imports to sales %7.40-   
Net fx Rs m-24,1220-   
CASH FLOW
From Operations Rs m3,449144,292 2.4%  
From Investments Rs m-8,802-345,491 2.5%  
From Financial Activity Rs m6,986194,116 3.6%  
Net Cashflow Rs m934-7,083 -13.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.33 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: DISHMAN PHARMA  ALKEM LABORATORIES  TTK HEALTHCARE  BIOCON LTD  FULFORD INDIA  



Today's Market

Share Markets in India End Flat; Dr Reddy's & Tata Steel Top Gainers(Closing)

Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement.

Related Views On News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

180,000%: The Returns That Could Have Been(The 5 Minute Wrapup)

Sep 7, 2017

For successful investing in small caps, it's important to know when not to press the panic button.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 20, 2017 03:36 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - NATCO PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS